Warning letterPosted July 21, 2026

FDA warning letter to Fareva Amboise

CGMP/Finished Pharmaceuticals/Adulterated

FDA's record ↗

FDA posted a warning letter to Fareva Amboise on July 21, 2026; the letter is dated April 10, 2026. Subject: CGMP/Finished Pharmaceuticals/Adulterated. Issuing office: Center for Veterinary Medicine.

On the record

Company
Fareva Amboise
Subject
CGMP/Finished Pharmaceuticals/Adulterated
Issuing office
Center for Veterinary Medicine
Letter dated
2026-04-10
Posted by FDA
2026-07-21
Source
FDA warning letters ↗

CFR cited

The record cites 5 sections of 21 CFR Parts 210 and 211.

The full record

An account shows the violations FDA described and each CFR section it cited.

What a warning letter is

A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.

More

Watch Fareva Amboise

A free account shows the last 7 days of every FDA, SEC and ClinicalTrials.gov source. Pro adds a watchlist: one email when FDA acts on a company you name.

From FDA warning letters. The record may have changed since it was read.

Approve Suite is not affiliated with FDA, or with Fareva Amboise. Informational only.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.